FR2416015A1 - Composition bactericide comprenant un anticorps de type igg, utile pour la prevention et le traitement du rhumatisme articulaire - Google Patents

Composition bactericide comprenant un anticorps de type igg, utile pour la prevention et le traitement du rhumatisme articulaire

Info

Publication number
FR2416015A1
FR2416015A1 FR7902807A FR7902807A FR2416015A1 FR 2416015 A1 FR2416015 A1 FR 2416015A1 FR 7902807 A FR7902807 A FR 7902807A FR 7902807 A FR7902807 A FR 7902807A FR 2416015 A1 FR2416015 A1 FR 2416015A1
Authority
FR
France
Prior art keywords
prevention
treatment
antibody
useful
composition consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7902807A
Other languages
English (en)
Other versions
FR2416015B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stolle Research and Development Corp
Original Assignee
Stolle Research and Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Research and Development Corp filed Critical Stolle Research and Development Corp
Publication of FR2416015A1 publication Critical patent/FR2416015A1/fr
Application granted granted Critical
Publication of FR2416015B1 publication Critical patent/FR2416015B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Produit pour le traitement et la prévention du rhumatisme articulaire. Selon l'invention, on réalise une immunisation passive contre une gamme variée de bactéries infectieuses qui résident dans les voies gastro-intestinales de l'homme, grâce à l'ingestion orale d'immunoglobuline IgG obtenue à partir du lait de vaches qui ont été immunisées contre une gamme spécifique de types de bactéries. Une combinaison particulière des espèces bactériennes est formulée en un vaccin qui est utilisé pour immuniser les vaches laitières. L'anticorps de type IgG obtenu à partir du lait des vaches immunisées constitue le produit de l'invention. Application à la prévention et au traitement du rhumatisme articulaire.
FR7902807A 1978-02-06 1979-02-02 Composition bactericide comprenant un anticorps de type igg, utile pour la prevention et le traitement du rhumatisme articulaire Granted FR2416015A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87514078A 1978-02-06 1978-02-06

Publications (2)

Publication Number Publication Date
FR2416015A1 true FR2416015A1 (fr) 1979-08-31
FR2416015B1 FR2416015B1 (fr) 1983-06-17

Family

ID=25365266

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7902807A Granted FR2416015A1 (fr) 1978-02-06 1979-02-02 Composition bactericide comprenant un anticorps de type igg, utile pour la prevention et le traitement du rhumatisme articulaire

Country Status (10)

Country Link
JP (1) JPS54113425A (fr)
CH (1) CH651210A5 (fr)
DE (1) DE2904044C2 (fr)
DK (1) DK158138C (fr)
FR (1) FR2416015A1 (fr)
GB (1) GB2013691B (fr)
HK (1) HK30283A (fr)
IT (1) IT1116524B (fr)
NL (1) NL7900766A (fr)
SE (1) SE448344B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732757A (en) * 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
ATE14269T1 (de) * 1981-02-26 1985-08-15 Unilever Nv Verfahren und vorrichtung zur rueckgewinnung von immunoglobulinen.
ATE16349T1 (de) * 1981-04-28 1985-11-15 Stolle Res & Dev Verfahren zur herstellung einer entzuendungshemmenden rindermilch.
JP2561234B2 (ja) * 1981-05-12 1996-12-04 スト−ル・リサ−チ・アンド・デイベロップメント・コ−ポレ−ション 抗炎症剤
JPS58154513A (ja) * 1982-03-09 1983-09-14 Sendai Biseibutsu Kenkyusho 予防及び治療薬
US4636384A (en) * 1982-06-03 1987-01-13 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
ATE39842T1 (de) * 1983-06-07 1989-01-15 Stolle Res & Dev Desodorant das bakterielle antikoerper enthaelt.
JPS6112629A (ja) * 1984-06-28 1986-01-21 Lion Corp 口腔内組成物
DE3785033T2 (de) * 1987-07-21 1993-10-07 Stolle Res & Dev Verfahren zum Erhalten von immunregulierenden Faktoren mittels Säugetierimmunisierung.
JP2664906B2 (ja) * 1987-08-13 1997-10-22 ストール・リサーチ・アンド・デイベロップメント・コーポレーション 改良された哺乳類の免疫法
JP2002542205A (ja) * 1999-04-19 2002-12-10 リチャード ワイスバート、 貯蔵ヒト免疫グロブリンおよび制酸剤の経口投与による成人リウマチ様関節炎の処置
EP1341552A2 (fr) * 2000-09-28 2003-09-10 Research Corporation Technologies, Inc Traitement des maladies d'origine immunologique au moyen de l'administration par voie orale de fractions de plasma
CA2437099A1 (fr) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Procedes et compositions destines au traitement de dysfonctions immunitaires
EP1357943A2 (fr) * 2001-01-30 2003-11-05 The Lauridsen Group Incorporated Procedes et compositions destines a moduler le systeme immunitaire des animaux
JP4960632B2 (ja) * 2006-01-10 2012-06-27 学校法人北里研究所 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物
JP5361132B2 (ja) * 2006-03-10 2013-12-04 国立大学法人信州大学 免疫グロブリンｇを含有する経口用免疫調節剤、その製造方法及び経口用免疫調節剤を配合してなる飲食品
JP2008179572A (ja) * 2007-01-25 2008-08-07 Shinshu Univ 免疫グロブリンＦｃフラグメントレセプタータンパク及び／又は免疫グロブリンＦｃフラグメントレセプター様タンパク産生抑制剤及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH488013A (de) * 1965-10-24 1970-03-31 Immune Milk Company Of America Verfahren zur Herstellung von Antitoxinen
DE1617769A1 (de) * 1967-06-10 1971-04-01 Rehm Eberhard Verfahren zur Gewinnung von spezifischen Antikoerper enthaltender Milch und daraus hergestellter Praeparate
JPS5136326A (ja) * 1974-09-24 1976-03-27 Komatsu Seiren Co Seikeigorufubooru
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS521014A (en) * 1975-06-17 1977-01-06 Stolle Res & Dev Pharmaceutically acceptable carrier containing milk immunoglobulin
JPS5381613A (en) * 1976-12-28 1978-07-19 Green Cross Corp:The Remedies for enteral infection diseases
CH627079A5 (en) * 1977-04-15 1981-12-31 Nestle Sa Process for preparing a protein concentrate containing immunological factors of milk origin

Also Published As

Publication number Publication date
GB2013691B (en) 1982-08-18
SE448344B (sv) 1987-02-16
DE2904044C2 (de) 1986-02-06
JPS54113425A (en) 1979-09-05
DK158138C (da) 1990-08-27
GB2013691A (en) 1979-08-15
JPH0160455B2 (fr) 1989-12-22
IT7947888A0 (it) 1979-02-05
NL7900766A (nl) 1979-08-08
CH651210A5 (de) 1985-09-13
DE2904044A1 (de) 1979-08-30
SE7900798L (sv) 1979-08-07
DK49479A (da) 1979-08-07
DK158138B (da) 1990-04-02
FR2416015B1 (fr) 1983-06-17
IT1116524B (it) 1986-02-10
HK30283A (en) 1983-09-02

Similar Documents

Publication Publication Date Title
FR2416015A1 (fr) Composition bactericide comprenant un anticorps de type igg, utile pour la prevention et le traitement du rhumatisme articulaire
US5538729A (en) Oral treatment of helicobacter infection
Lehner et al. Local passive immunization by monoclonal antibodies against streptococcal antigen I/II in the prevention of dental caries
Strockbine et al. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli
Abraham et al. Protection against Escherichia coli-induced urinary tract infections with hybridoma antibodies directed against type 1 fimbriae or complementary D-mannose receptors
IL91525A0 (en) Transgenic plants,pharmaceutical compositions containing the same and methods for the preparation thereof
EP0871484A1 (fr) Preparation de lait provenant de vaches immunisees, destinee a la prophylaxie de l'otite
Marcotte et al. Passive immunization: toward magic bullets
HU201927B (en) Process for producing mycophenolic acid-(morpholinoethyl)-ester and its derivatives, as well as pharmaceutical compositions comprising such compounds
HU202927B (en) Process for producing human monoclonal antibodies against serotypical lipopolysaccharide-determinants of gram-negative bacteria
Okuda et al. Protective efficacy of active and passive immunizations against experimental infection with Bacteroides gingivalis in ligated hamsters
EP0046909B1 (fr) Composition pharmaceutique
LU86711A1 (fr) Anticorps monoclonaux a reaction croisee et protection croisee vis-a-vis des serotypes de p.aeruginosa
Casswall et al. Bovine anti-Helicobacter pylori antibodies for oral immunotherapy
US6663873B2 (en) Antigenic preparation for treatment or prevention of helicobacter infection
Shimazaki et al. Passive immunization with milk produced from an immunized cow prevents oral recolonization by Streptococcus mutans
Boesman-Finkelstein et al. Bovine lactogenic immunity against cholera toxin-related enterotoxins and Vibrio cholerae outer membranes
Mitoma et al. Passive immunization with bovine milk containing antibodies to a cell surface protein antigen-glucosyltransferase fusion protein protects rats against dental caries
US6124132A (en) Use of anti-HIV IGA antibodies for producing immunological protection against the human immunodeficiency virus
Cantey Prevention of bacterial infections of mucosal surfaces by immune secretory IgA
Janson et al. Biological properties of yolk immunoglobulins
ES2274966T3 (es) Igy anti-pytyrosporum ovale y sus usos.
CA2033085A1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
Westerink et al. The thymus-dependent nature of the murine antibody response to a monoclonal anti-idiotypic antibody to the Neisseria meningitidis serogroup C capsular polysaccharide
DE69823638D1 (de) Oralprodukt zur Prävention und Behandlung von ansteckender Gastroenteritis in Kälbern